Silicon Investor
SI
SI
Advertise on SI

 Biotech / Medical : Biotech Valuation

 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  
To: Jack Hartmann who wrote (30830)4/3/2009 3:37:52 PM
From: Biomaven2 Recommendations  Read Replies (1) of 40320
 
The DNDN implied volatilities on their options are indicating a significant May event, so that would be consistent with the Apr 28 meeting.

At the end of the day, even if their results are good I could see the FDA giving them a hard time on the manufacturing side. But shorting a pop on good news could also be very hazardous given how crowded a short this is. So I personally don't see myself playing this one in either direction. (I generally believe it's a lot easier to make money in biotech with stocks that few people are talking about rather than ones with active and vociferous followers and detractors).

Peter
Report TOU ViolationShare This Post
 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQ
Copyright © 1995-2013 Knight Sac Media. All rights reserved.